PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy
NCT00742352 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2008-09-09
Summary
The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.
Conditions
Sponsors & Collaborators
-
Tel-Aviv Sourasky Medical Center
lead OTHER_GOV
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-09-30
Countries
- Israel
Study Locations
More Related Trials
-
PET/CT Evaluation of Treatment Response in Breast Cancer
NCT01222416 ·Status: TERMINATED ·Phase: NA
-
FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer
NCT02995902 ·Status: COMPLETED ·Phase: NA
-
Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT
NCT01000181 ·Status: SUSPENDED
-
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
NCT02146222 ·Status: COMPLETED ·Phase: PHASE1
-
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries
NCT02247713 ·Status: UNKNOWN
-
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
NCT02377934 ·Status: COMPLETED
-
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
NCT03846167 ·Status: ACTIVE_NOT_RECRUITING
-
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)
NCT00201942 ·Status: COMPLETED ·Phase: PHASE3
-
[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers
NCT04320030 ·Status: COMPLETED ·Phase: PHASE2
-
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
NCT04316117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
NCT07238322 ·Status: COMPLETED
-
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers
NCT00230269 ·Status: COMPLETED
-
Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT01179360 ·Status: COMPLETED
-
PET Imaging of Inflammation and Lipid Lowering Study
NCT04073797 ·Status: RECRUITING ·Phase: NA
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
NCT02055586 ·Status: COMPLETED
-
Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?
NCT03068520 ·Status: UNKNOWN ·Phase: NA
-
The Utility of FDG-PET for Radiation Treatment in NSCLC
NCT00385164 ·Status: UNKNOWN
-
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
NCT00346125 ·Status: COMPLETED ·Phase: NA
-
PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer
NCT04564482 ·Status: RECRUITING ·Phase: NA
-
PD-L1 PET Imaging in Melanoma Patients
NCT03520634 ·Status: COMPLETED ·Phase: NA
-
Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)
NCT01150006 ·Status: COMPLETED
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
NCT00935090 ·Status: RECRUITING
-
Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer
NCT00934401 ·Status: WITHDRAWN
-
PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
NCT01712815 ·Status: TERMINATED ·Phase: NA